



Human Cytochrome P450 and Personalized Medicine

Guest Editors:

Prof. Dr. Jacques Turgeon

1. Precision Pharmacotherapy
Research & Development
Institute, Tabula Rasa
HealthCare, Orlando, FL 32827,
USA

2. Faculty of Pharmacy,
Université de Montréal, Montréal,
QC H3C 3J7, Canada

Dr. Véronique Michaud

1. Precision Pharmacotherapy
Research & Development
Institute, Tabula Rasa
HealthCare, Orlando, FL 32827,
USA

2. Faculty of Pharmacy,
Université de Montréal, Montréal,
QC H3C 3J7, Canada

Deadline for manuscript
submissions:

closed (31 January 2023)

Message from the Guest Editors

It is our pleasure to invite you to contribute to a Special Issue of the *JPM* (IF 4.945) entitled Human CYP450s and Personalized Medicine. We provide you with this invitation as we know you are an expert in the field, and believe that you could contribute a significant paper to this Issue, which can hopefully be published as a book. A regular peer-review process will be in place, and you will receive comments following your submission. As a high-impact journal, publication is therefore not guaranteed.

Our objective is to have several publications covering the impact of variant alleles of various CYP450 isoforms on the pharmacokinetics, pharmacodynamics and patient outcomes associated with numerous medications. Hopefully, we will have publications covering at least *CYP1A2*, *CYP2B6*, *CYP2C9*, *CYP2C19*, *CYP2D6*, *CYP2E1*, *CYP2J2*, *CYP3A4/5* and *CYP4F2*. More than one paper for each isoform would be acceptable if they address conditions associated with different drugs. We urge you to let us know your topic of interest by submitting a title and a short abstract of the proposed publication (150 words). The deadline for submitting your work, either review or original article, is June 2022.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA

2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)